Logo image of ORTX

ORCHARD THERAPEUTICS PLC-ADR (ORTX) Stock Fundamental Analysis

NASDAQ:ORTX - Nasdaq - US68570P2002 - ADR - Currency: USD

16.7  +0.05 (+0.3%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ORTX. ORTX was compared to 571 industry peers in the Biotechnology industry. ORTX has a bad profitability rating. Also its financial health evaluation is rather negative. ORTX shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ORTX had negative earnings in the past year.
ORTX had a negative operating cash flow in the past year.
In the past 5 years ORTX always reported negative net income.
In the past 5 years ORTX always reported negative operating cash flow.
ORTX Yearly Net Income VS EBIT VS OCF VS FCFORTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M -200M

1.2 Ratios

ORTX has a Return On Assets of -36.05%. This is in the better half of the industry: ORTX outperforms 64.76% of its industry peers.
With a Return On Equity value of -90.81%, ORTX perfoms like the industry average, outperforming 44.86% of the companies in the same industry.
Industry RankSector Rank
ROA -36.05%
ROE -90.81%
ROIC N/A
ROA(3y)-55.93%
ROA(5y)-54.34%
ROE(3y)-102.43%
ROE(5y)-87.19%
ROIC(3y)N/A
ROIC(5y)N/A
ORTX Yearly ROA, ROE, ROICORTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -1K -2K -3K -4K

1.3 Margins

Looking at the Gross Margin, with a value of 69.19%, ORTX belongs to the top of the industry, outperforming 82.97% of the companies in the same industry.
ORTX's Gross Margin has been stable in the last couple of years.
ORTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5YN/A
ORTX Yearly Profit, Operating, Gross MarginsORTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

ORTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ORTX has been increased compared to 1 year ago.
ORTX has a worse debt/assets ratio than last year.
ORTX Yearly Shares OutstandingORTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M
ORTX Yearly Total Debt VS Total AssetsORTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

2.2 Solvency

ORTX has an Altman-Z score of -5.75. This is a bad value and indicates that ORTX is not financially healthy and even has some risk of bankruptcy.
ORTX has a worse Altman-Z score (-5.75) than 69.31% of its industry peers.
ORTX has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ORTX (0.20) is worse than 69.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z -5.75
ROIC/WACCN/A
WACC8.34%
ORTX Yearly LT Debt VS Equity VS FCFORTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M 300M

2.3 Liquidity

ORTX has a Current Ratio of 3.12. This indicates that ORTX is financially healthy and has no problem in meeting its short term obligations.
ORTX has a Current ratio of 3.12. This is in the lower half of the industry: ORTX underperforms 67.62% of its industry peers.
A Quick Ratio of 2.98 indicates that ORTX has no problem at all paying its short term obligations.
The Quick ratio of ORTX (2.98) is worse than 67.96% of its industry peers.
Industry RankSector Rank
Current Ratio 3.12
Quick Ratio 2.98
ORTX Yearly Current Assets VS Current LiabilitesORTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

ORTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.01%, which is quite impressive.
The Revenue has grown by 35.23% in the past year. This is a very strong growth!
Measured over the past years, ORTX shows a very strong growth in Revenue. The Revenue has been growing by 108.22% on average per year.
EPS 1Y (TTM)71.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.46%
Revenue 1Y (TTM)35.23%
Revenue growth 3Y108.22%
Revenue growth 5YN/A
Sales Q2Q%9%

3.2 Future

The Earnings Per Share is expected to grow by 14.90% on average over the next years. This is quite good.
ORTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 54.70% yearly.
EPS Next Y74.37%
EPS Next 2Y32.68%
EPS Next 3Y25.41%
EPS Next 5Y14.9%
Revenue Next Year24%
Revenue Next 2Y58.1%
Revenue Next 3Y63.4%
Revenue Next 5Y54.7%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ORTX Yearly Revenue VS EstimatesORTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
ORTX Yearly EPS VS EstimatesORTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ORTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ORTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORTX Price Earnings VS Forward Price EarningsORTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORTX Per share dataORTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as ORTX's earnings are expected to grow with 25.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.68%
EPS Next 3Y25.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ORTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORCHARD THERAPEUTICS PLC-ADR

NASDAQ:ORTX (1/23/2024, 8:00:02 PM)

16.7

+0.05 (+0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2023-11-13/bmo
Earnings (Next)03-05 2024-03-05/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.41%
Ins Owner Change0%
Market Cap380.11M
Analysts45.71
Price Target16.32 (-2.28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-22.67%
Min EPS beat(2)-96.08%
Max EPS beat(2)50.75%
EPS beat(4)3
Avg EPS beat(4)14.05%
Min EPS beat(4)-96.08%
Max EPS beat(4)72.21%
EPS beat(8)3
Avg EPS beat(8)-8.59%
EPS beat(12)6
Avg EPS beat(12)-4.49%
EPS beat(16)8
Avg EPS beat(16)-0.59%
Revenue beat(2)1
Avg Revenue beat(2)-6.14%
Min Revenue beat(2)-21.69%
Max Revenue beat(2)9.41%
Revenue beat(4)2
Avg Revenue beat(4)-15.77%
Min Revenue beat(4)-79.77%
Max Revenue beat(4)28.97%
Revenue beat(8)6
Avg Revenue beat(8)10.15%
Revenue beat(12)6
Avg Revenue beat(12)-24.54%
Revenue beat(16)8
Avg Revenue beat(16)90.73%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-85.82%
EPS NQ rev (3m)-85.82%
EPS NY rev (1m)-75.68%
EPS NY rev (3m)-75.68%
Revenue NQ rev (1m)12.87%
Revenue NQ rev (3m)12.87%
Revenue NY rev (1m)6.57%
Revenue NY rev (3m)6.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.4
P/FCF N/A
P/OCF N/A
P/B 4.73
P/tB 4.94
EV/EBITDA N/A
EPS(TTM)-4
EYN/A
EPS(NY)-2.75
Fwd EYN/A
FCF(TTM)-4.15
FCFYN/A
OCF(TTM)-4.1
OCFYN/A
SpS0.96
BVpS3.53
TBVpS3.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.05%
ROE -90.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.19%
FCFM N/A
ROA(3y)-55.93%
ROA(5y)-54.34%
ROE(3y)-102.43%
ROE(5y)-87.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5YN/A
F-Score3
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.82%
Cap/Sales 4.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.12
Quick Ratio 2.98
Altman-Z -5.75
F-Score3
WACC8.34%
ROIC/WACCN/A
Cap/Depr(3y)157.32%
Cap/Depr(5y)213.58%
Cap/Sales(3y)90.43%
Cap/Sales(5y)127.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.46%
EPS Next Y74.37%
EPS Next 2Y32.68%
EPS Next 3Y25.41%
EPS Next 5Y14.9%
Revenue 1Y (TTM)35.23%
Revenue growth 3Y108.22%
Revenue growth 5YN/A
Sales Q2Q%9%
Revenue Next Year24%
Revenue Next 2Y58.1%
Revenue Next 3Y63.4%
Revenue Next 5Y54.7%
EBIT growth 1Y21.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.57%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.86%
OCF growth 3YN/A
OCF growth 5YN/A